10 results about "Sertraline" patented technology

The present invention relates to a pharmaceutical composition including sertraline or a salt thereof. The pharmaceutical composition according to the present invention can achieve excellent stability and safety by inhibiting the generation of impurities of nitrosamines.

The invention discloses a nicardipine delivery system and application of the nicardipine delivery system in resisting post-traumatic stress disorder. According to the present invention, the functional modification is performed on the PLGA-PEG to develop the brain enrichment type PLGA-PEG-MANNOse molecule, the nicardipine is subjected to nanometer modification, the blood brain barrier permeability is enhanced, and the fear memory disorder of the post-traumatic stress disorder model animal can be effectively relieved; research finds that when PPM-N is used for treating mice related to electric shock complicated post-traumatic stress disorder, indexes of multiple experimental results are equivalent to serotonin reuptake inhibitor medicine sertraline. Related experiments show that PPM-N has the effect of treating and / or relieving post-traumatic stress disorder and has a good clinical application prospect.

The invention discloses an application of CHIR-090 in preparation of a pharmaceutical composition or a vaccine for treating and / or preventing vibrio parahaemolyticus infection. The MIC value of the small molecule drug CHIR-090 is 0.2 [mu] M, and compared with some antibiotics such as sertraline and conicillacin which are clinically used at present and used for treating vibrio parahaemolyticus infection, the MIC value of the small molecule drug CHIR-090 is extremely small. Results of an in-vitro killing and bacteriostatic activity experiment and a motility experiment show that the small molecule drug CHIR-090 has a certain effect on reduction of the number of bacteria and limitation of movement. The experiment result of zebra fish infection also shows that the small molecule drug CHIR-090 has better safety and bacteriostatic activity. Therefore, the small molecule drug CHIR-090 has a relatively good potential application value in inhibiting the activity of the vibrio parahaemolyticus.

Autism (ASD) symptoms of aggression-toward others or self, and paranoia with social isolation, are presently treated with antipsychotic medications such as haloperidol, Thorazine, and newer generation antipsychotics risperidone and aripiprazole (latter two are the only FDA approved drugs for treating autism irritability / aggression). But these antipsychotics including the newer generation, after a two or more years of use, often lead to irreversible tardive dyskinesia, other dystonias, loss of effectiveness, and brain volume loss. The present invention overcomes the irreversible tardive dyskinesia and dystonias and loss of effectiveness with long term-use of antipsychotics, by replacing the antipsychotic completely with a three (3) drug novel composition consisting of fluoxetine or sertraline with guanfacine and oxcarbazepine. This novel composition markedly reduces aggression and paranoia / social isolation in ASD adults and adolescents without concomitant antipsychotic use that often causes irreversible tardive dyskinesia, eventual tachyphylaxis, or brain volume loss from antipsychotic long-term use.

The application discloses a method for simultaneously detecting the concentration of six drugs in blood, comprising the following steps: S1, taking a blood sample, centrifuging, and adding methanol to precipitate protein; S2, preparing a series of concentration calibration solution, quality control sample and internal standard working solution; S3, adding the internal standard working solution to the supernatant 1 prepared in S1, vortex mixing, centrifuging, and taking the supernatant 2; S4, using high performance liquid chromatography-tandem mass spectrometry to detect the supernatant 2 obtained in S3 for the selected drugs, and performing mass spectrometry screening analysis on the basis of the retention time of the compound, two pairs or three pairs of parent ions / daughter ions; the drugs include one, multiple or all of fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram and escitalopram; the detection method provided by the application has the characteristics of simple and convenient sample pretreatment, small required sample volume, high sensitivity, high accuracy and high throughput.

The invention discloses an application of ergomine in preparation of a medicine for treating post-traumatic stress disorder caused by electric shock. According to the method, a post-traumatic stress disorder model is firstly constructed, and the result shows that in post-traumatic stress disorder model animals, remarkable core behavior characteristics such as fear overconsolidation memory and the like are shown. The ergotramine is used for intervention treatment, so that the fear memory fading capability of the model animal is obviously improved; behavior experiment comprehensive evaluation shows that the stiffness time of animals in an ergotramine treatment group is remarkably shortened. Experimental results show that the ergotramine can effectively relieve fear memory disorder of post-traumatic stress disorder model animals. Research finds that when the ergotramine is used for treating mice related to the electric shock complicated post-traumatic stress disorder, the index of an experimental result is superior to that of serotonin reuptake inhibitor medicine sertraline. Related experiments show that the ergotramine has the effect of treating and / or relieving post-traumatic stress disorder and has a good clinical application prospect.

Cancer progression involves changes in the composition of the lysosomal membrane. Under those stress conditions, several adaptive responses are activated to support cell survival, such as the transcription factor EB (TFEB) to drive the expression of lysosomal and autophagy related genes. In cases where these adaptive stress responses fail to cope with lysosomal stress, the induction of lysosomal damage can result in cell death. In the present invention, the inventors used 1200 FDA approved compounds for a high-content imaged-based screen to search new TFEB inducers and autophagy activators. They identified two compounds (Sertraline and Indatraline) that, despite the activation of TFEB and the high levels of LC3 puncta, elicited a significant cytotoxic effect in cancer cell lines. The data showed that both compounds inhibited autophagy flux partially and subsequently generated a significant induction of lysosomal membrane permeabilization and cell death. Finally, the inventors demonstrated that the compounds elicited immunogenic cell death features and mice that were vaccinated with these compounds were protected against tumor growth. These results indicate that both compounds have a stimulating effect on immunity against cancer.

The invention provides a sertraline derivative, an antigen, an antibody and a preparation method and application thereof, and belongs to the field of in-vitro detection. The structure of the sertraline derivative is shown as a formula A. According to the invention, the sertraline derivative is coupled with a carrier protein to obtain a sertraline antigen, and the sertraline antigen is used for animal immunization to obtain a monoclonal antibody. The sertraline antigen and the sertraline antibody can be used for carrying out chemiluminescence immunodetection on sertraline, and the detection method is wide in detection concentration range, high in precision, good in repeatability and simple and convenient to operate and better meets the requirements of clinical popularization. # imgabs0 #

The present disclosure provides a method of treating or reducing a disease or disorder in a subject in need thereof, comprising administering to the subject a composition comprising sertraline and a crystalline form of psilocybin, wherein the crystalline form is co-crystal Form A of sertraline and psilocybin. The present disclosure further provides a method of stimulating induced neural plasticity, increasing BDNF levels, and / or reducing neuroinflammation.

The invention provides a kit and a method for detecting the content of sertraline, and belongs to the technical field of in-vitro detection. The kit comprises the following components: (1) a reagent R1, wherein the reagent R1 comprises a sertraline antigen combined with a luminescent substance; (2) a reagent M1, wherein the reagent M1 comprises a sertraline antibody coupled with a fluorescent marker; wherein the structure of the sertraline antigen is shown as a formula C, and the sertraline antibody is an antibody generated in response to the sertraline antigen. The kit disclosed by the invention can be used for rapidly and quantitatively detecting the content of the sertraline medicine in samples such as blood, urine and saliva, is wide in detection concentration range, high in precision, good in repeatability and simple and convenient to operate, and better meets the requirements of clinical popularization. # imgabs0 #